OBJECTIVE: In the present study, we compared the effects of treatment with the novel soluble epoxide hydrolase (sEH) inhibitor (c-AUCB) with those of the AT1 receptor antagonist losartan on blood pressure (BP), autoregulation of renal blood flow (RBF) and on glomerular filtration rate (GFR) and the pressure-natriuresis relationship in response to stepwise reduction in renal arterial pressure (RAP) in Cyp1a1-Ren-2 transgenic rats. METHODS: Hypertension was induced in Cyp1a1-Ren-2 rats through dietary administration for 11 days of the natural xenobiotic indole-3-carbinol (I3C) which activates the renin gene. Treatment with c-AUCB and losartan was started 48 h before initiating administration of the diet containing I3C. Rats were prepared for renal functional studies to evaluate in-vivo renal autoregulatory efficiency when RAP was gradually decreased by an aortic clamp. RESULTS: I3C administration resulted in the development of severe hypertension which was associated with markedly lower basal RBF and GFR and substantially impaired autoregulatory efficiency as well as a suppression of the pressure-natriuresis relationship when compared with noninduced rats. Treatment with c-AUCB significantly decreased BP, improved autoregulatory efficiency of RBF and GFR and the slope of pressure-natriuresis relationship. Treatment with losartan completely prevented the impaired autoregulation and pressure-natriuresis relationship as well as the development of hypertension in I3C-induced rats. CONCLUSION: Our present findings indicate that chronic treatment with the sEH inhibitor c-AUCB substantially attenuates the development of malignant hypertension in I3C-induced rats likely via improvement of the renal autoregulatory efficiency and the pressure-natriuresis relationship.

Department for Experimental Medicine Institute for Clinical and Experimental Medicine Prague Czech Republic

Zobrazit více v PubMed

Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007;59:251–287. PubMed

Hall JE, Brands MW. The renin–angiotensin–aldosterone system: renal mechanisms and circulatory homeostasis. In: Seldin DW, Giebisch G, editors. The kidney: physiology and pathophysiology. Philadelphia: Lippincott Williams & Wilkins; 2000. pp. 1009–1046.

Ferreira AJ, Santos RAS, Bradford CN, Mecca AP, Sumners C, Katovich MJ, Raizada MK. Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases. Hypertension. 2010;55 :207–213. PubMed PMC

Castrop H, Höcherl K, Kurtz A, Schweda F, Todorov V, Wagner C. Physiology of kidney renin. Physiol Rev. 2010;90:607–673. PubMed

Guyton AC, Hall JE, Coleman TG, Manning RD., Jr . The dominant role of the kidneys in the long term regulation of arterial pressure in normal and hypertensive states. In: Laragh JH, Brenner BM, editors. Hypertension: pathophysiology, diagnosis and management. New York, NY: Raven Press, Publishers; 1990. pp. 1029–1052.

Navar LG, Majid DSW. Interactions between arterial pressure and sodium excretion. Curr Opin Nephrol Hypertens. 1996;5:64–71. PubMed

Cowley AW, Jr, Roman RJ. The role of the kidney in hypertension. J Am Med Assoc. 1996;275:1581–1589. PubMed

Ploth DW. Angiotensin-dependent renal mechanism in two-kidney, one-clip renal vascular hypertension. Am J Physiol. 1983;245:F131–F141. PubMed

Van der Mark J, Kline RL. Altered pressure natriuresis in chronic angiotensin II hypertension in rats. Am J Physiol. 1994;266:F739–F748. PubMed

Hall JE, Mizelle HL, Brands MV, Hildebrandt DA. Pressure natriuresis and angiotensin II in reduced kidney mass, salt-induced hypertension. Am J Physiol. 1992;262:R61–R71. PubMed

Mattson DL, Raff H, Roman RJ. Influence of angiotensin II on pressure natriuresis and renal hemodynamics in volume-expanded rats. Am J Physiol. 1991;29:R1200–R1209. PubMed

Wang CT, Chin SY, Navar LG. Impairment of pressure-natriuresis and renal autoregulation in ANG II-infused hypertensive rats. Am J Physiol. 2000;279:F319–F325. PubMed

Hall JE, Brands MW, Henegar JR. Angiotensin II and long-term arterial pressure regulation: the overriding dominance of the kidney. J Am Soc Nephrol. 1999;10:S258–S265. PubMed

Kantachuvesiri S, Fleming S, Peters J, Peters B, Brooker G, Lammie AG, et al. Controlled hypertension, a transgenic toggle switch reveals differential mechanisms underlying vascular disease. J Biol Chem. 2001;276:36727–36733. PubMed

Vaňourková Z, Kramer HJ, Husková Z, Vaněčková I, Opočenský M, Čertíková Chábová V, et al. AT1 receptor blockade is superior to conventional triple therapy in protecting against end-organ damage Cyp1a1-Ren-2 transgenic rats with inducible hypertension. J Hypertens. 2006;24:2465–2472. PubMed

Husková Z, Vaňourková Z, Erbanová M, Thumová M, Opočenský M, Mullins JJ, et al. Inappropriately high circulating and intrarenal angiotensin II levels during dietary salt loading exacerbate hypertension in Cyp1a1-Ren-2 transgenic rats. J Hypertens. 2010;28:495–509. PubMed

Honetschlagerová Z, Husková Z, Vaňourková Z, Sporková A, Kramer HJ, Hwang SH, et al. Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats with inducible hypertension. J Physiol. 2011;589:207–219. PubMed PMC

Mitchell KD, Bagatell SJ, Miller CS, Mouton CR, Seth DM, Mullins JJ. Genetic clamping of renin gene expression induces hypertension and elevation of intrarenal II levels of graded severity in Cyp1a1-Ren2 transgenic rats. JRAAS. 2006;7:74–86. PubMed

Campbell WB, Falck JR. Arachidonic acid metabolites as endothelium-derived hyperpolarizing factors. Hypertension. 2007;49:590–596. PubMed

Capdevila JH, Falck JR, Imig JD. Role of the cytochrome P450 arachidonic acid monooxygenases in the control of systemic blood pressure and experimental hypertension. Kidney Int. 2007;72:683–689. PubMed

Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev. 2002;82:131–185. PubMed

Imig JD, Zhao X, Falck JR, Wei S, Capdevila JH. Enhanced renal mircovascular reactivity to angiotensin II in hypertension is ameliorated by the sulfonimide analog of 11,12-epoxyeicosatrienoic acid. J Hypertens. 2001;19:983–992. PubMed

Imig JD. Targeting epoxides for organ damage in hypertension. J Cardiovasc Pharmacol. 2010;56:329–335. PubMed PMC

Hwang SH, Tsai HJ, Liu JY, Morisseau C, Hammock BD. Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem. 2007;50:3825–3840. PubMed PMC

Erbanová M, Thumová M, Husková Z, Vaněčková I, Vaňourková Z, Mullins JJ, et al. Impairment of the autoregulation of renal hemodynamics and of the pressure-natriuresis relationship precedes the development of hypertension in Cyp1a1-Ren-2 transgenic rats. J Hypertens. 2009;27 :575–586. PubMed

Williams DE, Minolfa CP, Mullins JJ, Navar LG, Mitchell KD. AT1 receptor blockade prevents the increase in blood pressure and the augmentation of intrarenal ANG II levels in hypertensive Cyp1a1-Ren-2 transgenic rats fed a high salt diet. Am J Med Sci. 2010;339:356–361. PubMed PMC

Čertíková Chábová V, Kramer HJ, Vaněčková I, Vernerová Z, Eis V, Tesař V, et al. Effects of chronic cytochrome P-450 inhibition on the course of hypertension and end-organ damage in Ren-2 transgenic rats. Vascul Pharmacol. 2007;47:145–149. PubMed

Čertíková Chábová V, Walkovska A, Kompanowska-Jezierska E, Sadowski J, Kujal P, Vernerová Z, et al. Combined inhibition of 20-hydroxy-eicosatetrenoic acid formation and epoxyeicosaetraenoic degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats. Clin Sci. 2010;118:617–632. PubMed PMC

Semple SJ, de Wardener HE. Effect of increased renal venous pressure on circulatory autoregulation of isolated dog kidneys. Circ Res. 1959;7:643–648. PubMed

Imig JD, Falck JR, Wei S, Capdevila JH. Epoxygenase metabolites contribute to nitric oxide-independent afferent arteriolar vasodilatation in response to bradykinin. J Vasc Res. 2001;38:247–255. PubMed

Kohagure K, Endo Y, Ito O, Arima S, Omata K, Ito S. Endogenous nitric oxide and epoxyeicosatrienoic acids modulate angiotensin II-induced constriction in the rabbit afferent arteriole. Acta Physiol Scand. 2000;168:107–112. PubMed

Madhun ZT, Goldthwait DA, McKay D, Hopfer U, Douglas JG. An epoxygenase metabolite of arachidonic acid mediates angiotensin II-induced rises in cytosolic calcium in rabbit proximal tubule epithelial cells. J Clin Invest. 1991;88:456–461. PubMed PMC

Sakairi Y, Jacobson HR, Noland DT, Capdevila JH, Falck JR, Breyer MD. 5,6-EET inhibits ion transport in collecting duct by stimulating endogenous prostaglandin synthesis. Am J Physiol. 1995;268:F931–F939. PubMed

Majid DSA, Navar LG. Blockade of distal nephron sodium transport attenuates pressure natriuresis in dogs. Hypertension. 1994;23:1040–1045. PubMed

Sporková A, Kopkan L, Varcabová A, Husková Z, Hwang SH, Hammock BD, et al. Role of cytochrome P450 metabolites in the regulation of renal function and blood pressure in 2-kidney, 1-clip hypertensive rats. Am J Physiol. 2011 epub ahead of print. PubMed PMC

Zhao X, Yamamoto T, Newman JW, Kim IH, Watanabe T, Hammock BD, et al. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. J Am Soc Nephrol. 2004;15:1244–1253. PubMed

Imig JD, Zhao X, Zaharis CZ, Olearczyk JJ, Pollock DM, Newman JW, et al. An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension. 2005;46:975–981. PubMed PMC

Kujal P, Čertíková Chábová V, Vernerová Z, Walkovska A, Kompanowska-Jezierska E, Sadowski J, et al. Similar renoprotection after renin-angiotensin-dependent and –independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects? Clin Exp Pharmacol Physiol. 2010;37:1159–1169. PubMed

Olearczyk JJ, Quigley JE, Mitchell BC, Yamamoto T, Kim IH, Newman JW, et al. Administration of a substituted adamantly urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats. Clin Sci. 2009;116:61–70. PubMed PMC

Renal sympathetic denervation improves pressure-natriuresis relationship in cardiorenal syndrome: insight from studies with Ren-2 transgenic hypertensive rats with volume overload induced using aorto-caval fistula

Impaired renal autoregulation and pressure-natriuresis: any role in the development of heart failure in normotensive and angiotensin II-dependent hypertensive rats?

Early Renal Vasodilator and Hypotensive Action of Epoxyeicosatrienoic Acid Analog (EET-A) and 20-HETE Receptor Blocker (AAA) in Spontaneously Hypertensive Rats

Epoxyeicosanoids in hypertension

20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats

Two pharmacological epoxyeicosatrienoic acid-enhancing therapies are effectively antihypertensive and reduce the severity of ischemic arrhythmias in rats with angiotensin II-dependent hypertension

Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease

Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats

Inhibition of soluble epoxide hydrolase does not improve the course of congestive heart failure and the development of renal dysfunction in rats with volume overload induced by aorto-caval fistula

Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: studies in Cyp1a1-Ren-2 transgenic rats

Inhibition of soluble epoxide hydrolase is renoprotective in 5/6 nephrectomized Ren-2 transgenic hypertensive rats

Antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats is mediated by suppression of the intrarenal renin-angiotensin system

Antihypertensive and renoprotective actions of soluble epoxide hydrolase inhibition in ANG II-dependent malignant hypertension are abolished by pretreatment with L-NAME

Soluble epoxide hydrolase inhibition exhibits antihypertensive actions independently of nitric oxide in mice with renovascular hypertension